Quarterly ResultAug 12, 2026, 06:02 AM
BioHarvest Secures CDMO Deal, Q2 Revenue Up 3.8% to $8.8M
AI Summary
BioHarvest Sciences Inc. reported Q2 2026 financial results, with revenue increasing 3.8% year-over-year to $8.8 million. The company secured its first CDMO manufacturing agreement for a 20-ton rare botanical fragrance production program, expected to drive profitable growth. Despite a net loss of $3.7 million, BioHarvest revised its full-year guidance, tightening CDMO revenue expectations while reducing its EBITDA loss, and adjusting VINIA D2C revenue downwards to prioritize profitability and manufacturing capacity.
Key Highlights
- Secured first CDMO manufacturing agreement for 20-ton rare botanical fragrance production over two years.
- Q2 2026 total revenues reached $8.8 million, a 3.8% increase from Q2 2025.
- Reported a Q2 2026 net loss of $3.7 million, an improvement from $4.1 million in Q2 2025.
- Revised full-year CDMO EBITDA loss guidance to $1.5-$2.5 million, down from $4-$5 million.
- Revised full-year VINIA D2C revenue guidance to $33-$35 million, down from $38-$42 million.
- Awarded a $1.4 million grant from the Israel Innovation Authority for AI and automation.
- Cash and cash equivalents totaled $16.25 million as of June 30, 2026, up from $3.7 million last year.
Price Impact
More from BHST